Forster, Martin

Tracking the Evolution of Non–Small-Cell Lung Cancer

Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 2,349

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 1,298

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., et al. (2014) · Science

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 1,117

Lung adenocarcinoma promotion by air pollutants

Hill, W., Lim, E. L., Weeden, C. E., Lee, C., Augustine, M., Chen, K., Kuan, F.-C., Marongiu, F., Evans, E. J., Moore, D. A., et al. (2023) · Nature

Air Quality and Health ImpactsCarcinogens and Genotoxicity Assessment

Cited by 808

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 592

Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study

Lai, A. G., Pasea, L., Banerjee, A., Hall, G., Denaxas, S., Chang, W. H., Katsoulis, M., Williams, B., Pillay, D., Noursadeghi, M., et al. (2020) · BMJ Open

COVID-19 and healthcare impactsGlobal Cancer Incidence and Screening

Cited by 447

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

Abbosh, C., Frankell, A. M., Harrison, T., Kisistok, J., Garnett, A., Johnson, L., Veeriah, S., Moreau, M., Chesh, A., Chaunzwa, T. L., et al. (2023) · Nature

Cancer Genomics and DiagnosticsLung Cancer Diagnosis and Treatment

Cited by 382

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

Sacher, A., LoRusso, P., Patel, M. R., Miller, W. H., Garralda, E., Forster, M. D., Santoro, A., Falcon, A., Kim, T. W., Paz-Ares, L., et al. (2023) · New England Journal of Medicine

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 328

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

de Bono, J. S., Concin, N., Hong, D. S., Thistlethwaite, F. C., Machiels, J.-P., Arkenau, H.-T., Plummer, R., Jones, R. H., Nielsen, D., Windfeld, K., et al. (2019) · The Lancet Oncology

Monoclonal and Polyclonal Antibodies ResearchLung Cancer Treatments and Mutations

Cited by 237

Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.

Zauderer, M. G., Szlosarek, P., Le Moulec, S., Popat, S., Taylor, P., Planchard, D., Scherpereel, A., Jahan, T., Koczywas, M., Forster, M., et al. (2018) · Journal of Clinical Oncology

Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies

Cited by 54

Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study

Forster, M. D., Dillon, M. T., Kocsis, J., Remenár, É., Pajkos, G., Rolland, F., Greenberg, J., & Harrington, K. J. (2019) · European Journal of Cancer

Head and Neck Cancer StudiesHER2/EGFR in Cancer Research

Cited by 32

Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study

Dillon, M. T., Grove, L., Newbold, K. L., Shaw, H., Brown, N. F., Mendell, J., Chen, S., Beckman, R. A., Jennings, A., Ricamara, M., et al. (2019) · Clinical Cancer Research

Head and Neck Cancer StudiesHER2/EGFR in Cancer Research

Cited by 16

Abstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation

Desai, J., Han, S.-W., Lee, J.-S., Shacham-Shmueli, E., Massarelli, E., Cervantes, A., Garralda, E., Falcon, A., Miller, W. H., Gort, E., et al. (2023) · Cancer Research

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 10